Bank of Montreal
VIRX

Bank of Montreal’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Bank of Montreal’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-590
Closed -$885K – 4206
2014
Q3 		$885K Buy
590
+134
+29% +$194K ﹤0.01% 1819
2014
Q2 		$624K Buy
+456
New +$529K ﹤0.01% 1975
2013
Q4 		– Sell
-26
Closed -$27K – 3958
2013
Q3 		$27K Buy
+26
New +$27.8K ﹤0.01% 3090

Other funds holding VIRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Bank of Montreal's VIRX Position: Q4 2014 in Review

Bank of Montreal sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2014, closing a stake of 140 shares — an estimated $210K sold.

Bank of Montreal first reported a position in VIRX in Q2 2013 and held it in 5 quarters. The position peaked at $557K in Q2 2014. 78 funds tracked by Wall St. Rank hold VIRX as of Q4 2014.

  • Bank of Montreal reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Bank of Montreal sold 140 Viracta Therapeutics, Inc. Common Stock shares in Q4 2014, an estimated $210K.
  • Bank of Montreal first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 5 quarters.
  • Bank of Montreal's Viracta Therapeutics, Inc. Common Stock position peaked at $557K in Q2 2014.
  • 78 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2014.

Based on Bank of Montreal's 13F filing for Q4 2014, filed 9 Feb 2015.